Edition:
United Kingdom

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Capital Market

8.32USD
15 Dec 2017
Change (% chg)

$0.33 (+4.13%)
Prev Close
$7.99
Open
$8.04
Day's High
$8.39
Day's Low
$7.92
Volume
227,554
Avg. Vol
190,487
52-wk High
$9.40
52-wk Low
$1.46

Summary

Name Age Since Current Position

Robert Wills

62 2015 Chairman of the Board

Sujal Shah

42 2017 President, Chief Executive Officer

Charles McWherter

62 Senior Vice President, Chief Scientific Officer

Daniel Menold

47 2017 Vice President - Finance, Principal Financial Officer, Principal Accounting Officer

Kirk Rosemark

44 2015 Vice President - Regulatory Affairs and Quality Assurance

Paul Quinlan

53 2017 General Counsel, Corporate Secretary

Pol Boudes

58 2014 Chief Medical Officer

Robert Booth

2016 Director

Caroline Loewy

2016 Director

Evan Stein

2016 Director

Paul Truex

2016 Director

Robert Weiland

57 2016 Director

Carl Goldfischer

58 2003 Independent Director

Hari Kumar

2012 Independent Director

Kurt von Emster

50 2009 Independent Director

Biographies

Name Description

Robert Wills

Dr. Robert James Wills, Ph.D. has been appointed as Chairman of the Board of the Company. He was an Independent Director of the Company., since March 2015. Dr. Wills was elected to the Board because of his extensive and significant experience over more than 35 years in the pharmaceutical industry, including preclinical and clinical research and development, business development and strategic partnering. Dr. Wills served in a variety of executive roles for Johnson & Johnson, or J&J, from December 1989 to February 2015 and recently served as Vice President, Alliance Manager where he was responsible for managing strategic alliances for J&J’s Pharmaceutical Group worldwide since 2002. Prior to this, Dr. Wills spent 22 years in pharmaceutical drug development, 12 of which were at J&J and 10 of which were at Hoffmann-La Roche Inc. Before assuming his role as Alliance Manager at J&J, Dr. Wills served as Senior Vice President Global Development at J&J where he was responsible for its late stage development pipeline and was a member of several internal commercial and research and development operating boards. Dr. Wills is a member of the Board of GTx, Inc., where he serves as Executive Chairman and Chair of the Scientific and Development Committee. Dr. Wills holds a B.S. in Biochemistry and a M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas.

Sujal Shah

Mr. Sujal Shah is President, Chief Executive Officer of the Company. Mr. Shah joined CymaBay as Chief Financial Officer in December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer since June 2012. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking Group for Citigroup, where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010, Mr. Shah was employed with Credit-Suisse, last serving as Vice President, Health Care Investment Banking Group. Mr. Shah received a MBA from Carnegie Mellon University Tepper School of Business and B.S. and M.S. degrees in biomedical engineering from Northwestern University. Mr. Shah currently serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.

Charles McWherter

Dr. Charles A. McWherter, Ph.D. is Senior Vice President and Chief Scientific Officer at Metabolex, Inc. (AKA: CymaBay Therapeutics). He has been Vice President of Nonclinical Development and Project Management since the inception of CymaBay in 2013. Prior to that he served as Vice President of Project and Portfolio Management at Metabolex (2008-2013), Senior Director of Preclinical Development and Project Management from 2006 to 2008 and Director of Preclinical Development and Project Management from 2004 to 2006. From 1994 to 2004, Dr. Martin served in various positions of increasing responsibility within Pharma Research and Global Development in Roche Palo Alto, a division of F. Hoffman-La Roche Ltd. Dr. Martin obtained his Ph D. in Biochemistry from the University of California, Davis.

Daniel Menold

Mr. Daniel Menold has been appointed as Vice President - Finance, Principal Financial Officer, Principal Accounting Officer of the Company. He has served as the Corporate Controller of CymaBay since January 2014. From 2011 to 2013, Mr. Menold served as Corporate Controller for Zoosk, Inc., a high growth, technology start-up, where he directed the accounting and reporting function. From 2005 to 2010, Mr. Menold was employed with Affymetrix, a public life sciences tools company, serving as Controller and Director of Accounting. Prior to 2005, Mr. Menold held accounting and finance positions of increasing responsibility at public and private life sciences and high technology companies in the Silicon Valley. Mr. Menold began his career in public accounting at Ernst & Young where he served life sciences and high technology companies as an audit manager. Mr. Menold received a M.S. in accounting and B.S. in finance from The University of Virginia McIntire School of Commerce.

Kirk Rosemark

Mr. Kirk Rosemark is Vice President - Regulatory Affairs and Quality Assurance of CymaBay Therapeutics, Inc. Mr. Rosemark comes to CymaBay with 20 years of regulatory affairs experience. He served as VP of Regulatory Affairs and Quality Assurance for Exelixis, Inc., where he played a key role in the clinical development and approval of COMETRIQ™ (cabozantinib). Prior to that, Mr. Rosemark served as VP, Regulatory Affairs at NeoPharm and Director of Regulatory Affairs at Unimed Pharmaceuticals, Inc. following its acquisition by Solvay Pharmaceuticals.

Paul Quinlan

Mr. Paul T. Quinlan is General Counsel, Corporate Secretary of the Company. Mr. Quinlan comes to CymaBay from Terravia Holdings, Inc. (formerly Solazyme, Inc.), where since 2010 he has served as General Counsel and Secretary, overseeing the legal function and providing assistance with all aspects of public company law, including biotechnology, compliance, corporate finance and IP law. From 2005 to 2010, Mr. Quinlan was the General Counsel and Secretary for Metabolex, Inc., where he provided business, strategic and legal advice to Board and company management. From 2000 to 2005 Mr. Quinlan was Chief Corporate Securities Counsel for Maxygen, Inc., where he was responsible for all securities law, compliance, commercial and corporate legal work. From 1994 to 2000, Paul was an associate at Cravath, Swaine, & Moore, LLP and then Cooley LLP, where he worked with biopharma and medical device companies. Mr. Quinlan obtained a law degree from Columbia University and a Masters of Science (M.Sc.) in Biophysics from the University of Toronto.

Pol Boudes

Dr. Pol Boudes is Chief Medical Officer of the Company. Prior to joining CymaBay, Dr. Boudes was Chief Medical Officer at Amicus Therapeutics, where he was responsible for clinical development, medical affairs and quality assurance and toxicology. From 2004 to 2009, Dr. Boudes was with Berlex Laboratories (which merged with Bayer HealthCare Pharmaceuticals in 2006) where he held the position of Vice President, Global Clinical Development, Women’s, Health Care US. From 1990 to 2004, he held positions of increasing responsibility with Wyeth-Ayerst Research both in Philadelphia, PA and in Europe, with Hoffmann-La Roche, and with Pasteur-Merieux Serums & Vaccines. Dr. Boudes received his M.D. from the University of Aix-Marseilles, France. He completed his internship and residency in Marseilles and in Paris, France and was an Assistant Professor of Medicine at the University of Paris., He is specialized in Endocrinology and Metabolic Diseases, Internal Medicine, and Geriatric diseases.

Robert Booth

Caroline Loewy

Evan Stein

Mr. Evan A. Stein M.D. Ph.D.

Paul Truex

Mr. Paul F. Truex has been appointed as Director of the Company., effective 1 April 2016. Paul Truex is currently President and CEO of Anthera Pharmaceuticals. He was responsible for negotiating Anthera's product licenses for both blisibimod, the company's anti-BAFF peptibody program from Amgen, and recently, Sollpura™, an enzyme replacement product from Eli Lilly & Company. During his career, Mr. Truex has been involved with over $500 million in financings and over $1 billion in strategic in-licensing, out-licensing, and merger and acquisition transactions. Prior to founding Anthera, he was a Founder, Director, President & CEO of Peninsula Pharmaceuticals. During that time, he negotiated both of Peninsula's product agreements with Shionogi & Co., Ltd. (Doribax®, doripenem) and Takeda Chemical Industries (Teflaro®, ceftaroline). Peninsula was sold to Johnson & Johnson for $245 million and the remaining entity, Cerexa, was subsequently acquired for $480 million. Prior to Peninsula, Mr. Truex was VP of Commercial Development of Versicor Incorporated (acquired by Pfizer) where he directed early commercial efforts in infectious disease. Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market. His business development experience includes the Lilly ICOS LLC joint venture for the development of Cialis® and two product divestitures (anidulafungin, Eraxis® and loracarbef, Lorabid®). Mr. Truex obtained a Master's of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo.

Robert Weiland

Mr. Robert J. Weiland has been appointed as Director of the Company., effective 1 April 2016. He is a seasoned commercial executive, having held senior leadership roles in both large-cap pharma and biotechnology companies. Most recently, Bob worked at Baxter International, where he served as Vice President, Strategy for Baxter International, and where he led the reconstruction of Baxter's worldwide go-to-market strategy. Prior to that, he was Baxter International's Vice President, Corporate Development where he was responsible for Baxter's global business development organization and shared leadership responsibilities for Baxter's $200 million Venture Fund. Bob initially joined Baxter as its Vice President, Strategy & Portfolio Planning for Baxter's BioScience business. In this role he led strategy development, including specialty therapeutics business development, and strategic portfolio management for Baxter's $5.6 billion Bioscience business, which has since been spun off as an independent biotechnology company, Baxalta. Prior to Baxter, Mr. Weiland was VP of Operations and Strategic Analytics for Takeda Pharmaceuticals North America. Before Takeda, he headed the clinical, commercial and operational activities for the Surgery business unit of The Medicines Company as its Vice President and General Manager. Prior to that, he served for more than 14 years in a variety of senior domestic and international Marketing, General Management and Business Development roles at Abbott Laboratories, including the in-licensing, launch and subsequent building of TriCor, the foundation of Abbott's lipid-lowering franchise. Mr. Weiland earned a Bachelor of Science Degree from DeSales University, Center Valley, Pennsylvania and a Master's in Business Administration in Finance and Marketing from The Wharton School at the University of Pennsylvania.

Carl Goldfischer

Dr. Carl Goldfischer, M.D. is the Independent Director of the Company since August 2003. Dr. Goldfischer was elected to the Board as a result of Bay City Capital’s investment in the company and his in depth knowledge of the pharmaceutical industry. Dr. Goldfischer is an investment partner and managing director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was chief financial officer of ImClone Systems Inc. Previously, he was a research analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer is a member of the board of directors for BrainCells Inc., Cydan, EnteroMedics Inc. and Epizyme, Inc. Dr. Goldfischer received a M.D. with honors in scientific research from Albert Einstein College of Medicine and a B.A. from Sarah Lawrence College.

Hari Kumar

Dr. Hari Kumar Ph.D. is an Independent Director of the Company., since September 2012. Dr. Kumar was elected to the Board as a result his in depth knowledge and experience in the pharmaceutical industry. Dr. Kumar has over 25 years of pharmaceutical experience. Dr. Kumar has served as Chief Executive Officer and Board Director of Adheron Therapeutics, Inc., since July 2013. Prior to that, he was Chief Executive Officer of Panmira Pharmaceuticals LLC from October 2011 until June 2013 and Chief Business Officer of Amira Pharmaceuticals, Inc. from 2007 until its acquisition by Bristol Meyer Squibb in 2011. Prior to that, Dr. Kumar worked at Hoffmann-La Roche Inc. serving in the capacity of research, sales and marketing, lifecycle management and finally to business development from 1999 until 2007. While with Roche, Dr. Kumar was involved in guiding 7 cross functional teams at Roche for the Transplantation franchise which resulted in the growth of the products in the franchise to achieve billion dollar sales. Dr. Kumar also identified and partnered valuable products that have enhanced Roche’s portfolio, including Isotechnika, Biotie, Biocryst and Actellion. Dr. Kumar has overseen the launch of the immunosuppressive, CellCept®, the Alzheimer’s drug, Aricept® and gastric ulcer drug, Aciphex®. During the period 1996 through 1999, Dr. Kumar worked for Eisai Ltd, as their European Marketing Director. Dr. Kumar trained as an immunologist at University College London where he completed his Ph.D., and he completed a postdoctoral fellowship at Tufts New England Medical Center in Boston and another fellowship at the Marie Curie Cancer Research Centre in UK.

Kurt von Emster

Mr. Kurt von Emster, CFA is an Independent Director since April 2009. Mr. von Emster was elected to the Board because of his in depth knowledge of the pharmaceutical industry where he has been an institutional biotechnology and health care analyst and portfolio manager for 25 years. Mr. von Emster has been a Partner at Abingworth LLC since January 2015. Prior to joining Abingworth, Mr. von Emster was a co-founder and Managing Partner of venBio LLC from May 2009 until January 2015. In 2001, Mr. von Emster became a General Partner at MPM Capital, a leading biotechnology private equity firm, and launched the MPM BioEquities Fund, a cross over public and private biotechnology hedge fund. He was the portfolio manager of this fund from inception in 2001 until his departure in 2009. Mr. von Emster’s investment career started in 1989 at Franklin Templeton Investments where he founded and managed several health and biotechnology funds in the 1990s, each achieving a 5-star Morningstar ranking. In 2000, he was managing over $2B in biotech and health care funds for Franklin Templeton. He is a member of the board of directors of CRISPR Therapeutics (private) and Cytos Biotechnology AG, a former member of the board of Aurinia Pharma, Facet Biotech Corporation (sold to Abbott Laboratories in 2010) and Somaxon Pharmaceuticals, Inc. (sold to Pernix Therapeutics Holdings, Inc. in 2013), and a former board observer of Acceleron Pharma Inc. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara.